Remely et al. investigated three groups of subjects: patients with T2D using glucagon-like peptide-1 (GLP-1) agonist therapy, obese individuals without established insulin resistance, and a normal-weight control group. This evidence concerns the gene GCG and type 2 diabetes mellitus.